

Language: English

Symposium fees:

AFPT-Le Club Phase 1 member fees
(2019 membership): **200 €**

Non-member fees: **300 €**

Academic student: **150 €**

Registration:

Required before: **Mars 15, 2019**

Registration form online on:

<https://clubphase1.com>

[https://www.linscription.com/activite.](https://www.linscription.com/activite.php?P1=15722)

[php?P1=15722](https://www.linscription.com/activite.php?P1=15722)

Limited number of seats!

If you have any questions, please
email us at leclubphase1@gmail.com

Location:

Maison de la Chimie

28, rue Saint Dominique

75007 PARIS - France

Phone : (+33)1 40 62 27 00



Access:

RER: Line C, Invalides Station

Subway: Lines 8, 12 et 13, Assemblée

Nationale, Solférino or Invalides Stations

Bus: Lines 63, 69, 73, 83, 84 and 94



Suggested accommodations:

Saint Dominique Hotel
62, rue Saint Dominique

Best Western Tour Eiffel Invalides
35, boulevard de la Tour Maubourg

Hôtel de Varenne
44, rue de Bourgogne

Booking directly with the hotel

AFPT – Le Club Phase I (Association by law 1901)
is a founding member of 



with the support of



&



present

PBPK SYMPOSIUM 2019

PARIS - APRIL 4, 2019

ACT 3

*Physiologically Based
Pharmacokinetic modelling (PBPK):
A new Paradigm in Drug Development*

sponsored by  **GENOPOLE**
VIVRE L'INNOVATION

PROGRAM

SESSION 1: Diverse Clinical Development Applications in Big Pharma

*Chairs: Henri Caplain (AFPT - Le Club Phase 1) -
Jean-Louis Pinquier (AFPT - Le Club Phase 1)*

- 8:30 AM Welcome coffee/tea
- 9:00 AM Mechanistic Oral Absorption Modelling
an update on cross-industry activities
Neil Parrott,
Modelling & Simulation Scientist,
Roche Innovation Center Basel
- 9:40 AM Developmental changes in drug
disposition and responses: the challenges
Jean-Marie Nicolas,
Director PK/IPD, Development Science Dpt,
UCB Biopharma SPRL
- 10:00 AM Break
- 10:30 AM F.I.H 4 F.I.H: Faith in Holistic
modelling for First-in-Human PK
Neil Miller,
DMPK Investigator-PBPK Leader,
GSK
- 11:40 AM Physiological Based Absorption
Modelling in industrial practice.
Current applications
and a vision for the future
Xavier Pepin,
Principal Scientist,
Astrazeneca
- 12:00 PM Questions & Answers
- 12:05 PM

SESSION 2: Early discovery (ADMET-PBPK), UGT metabolism

*Chairs: Neil Parrott (Roche) -
Jérémy Perrier (PhinC D.)*

- 12:05 PM Age-dependent variations in activity
of hepatic UGT enzymes: Application
to PBPK modelling
Justine Badee,
Post-doctoral Associate,
Roche/University of Florida
- 12:45 PM Lunch
- 2:00 PM Challenges of transporter IVIVE:
a digoxin example
Maelys De Sousa Mendes,
PhD, Research Scientist,
Simcyp
- 2:40 PM Discovery PBPK: Efficiently using
machine learning & PBPK
modeling to drive lead selection
& optimization
Viera Lukacova,
Director, Simulation Sciences,
Simulations Plus
- 3:00 PM Questions & Answers
- 3:05 PM

AFPT – Le Club Phase I (Association by law 1901)
is a founding member of 

SESSION 3: PBPK in special populations: Pediatric and pregnancy models

*Chairs: Florence GATTACCECA (Aix-Marseille
Université) - Benjamin Dupont (PhinC D.)*

- 3:05 PM Analysis of UGT activity changes
during pregnancy through PBPK
modeling
Andre Dallmann,
Scientist Systems Pharmacology,
Bayer
- 3:45 PM Paediatric and Pregnancy PBPK/PD
Modelling: Clinical and Drug
Development Applications
Trevor Johnson,
Principal Scientist,
Simcyp
- 4:25 PM Break
- 4:45 PM
- SESSION 4:
What's new for regulatory
requirements?
- 4:45 PM The finalised EMA guideline and
latest experience of PBPK models
in Regulatory submissions
Essam Kerwash,
MHRA
- 5:25 PM Questions & Answers
- 5:30 PM
- 5:30 PM Closing Remarks
- 6:00 PM